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Background: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for
metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we
carried out a meta-analysis using individual patient level trial data.
Methods: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016.
Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between
therapeutic agents on PFS and OS was investigated.
Results: OS data were available for 912 patients. The median PFS was 3.3months (95% CI 2.9–3.6) and 6-month PFS rate was
27% (95% CI 24–30). Univariable analysis showed male sex, elevated (i.e.> versus upper limit of normal) lactate
dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (3 cm versus<3 cm) to
be substantially associated with shorter PFS. Multivariable analysis showed male sex, elevated LDH and elevated ALP were
substantially associated with shorter PFS. The most substantial factors associated with 6-month PFS rate, on both univariable
and multivariable analysis were elevated LDH and ALP. The median OS was 10.2months (95% CI 9.5–11.0) and 1 year OS was
43% (95% CI 40–47). The most substantial prognostic factors for shorter OS by univariable and multivariable analysis were
elevated LDH and elevated ALP. Patients treated with liver directed treatments had statistically significant longer PFS and OS.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Conclusion: Benchmarks of 6-month PFS and 1-year OS rates were determined accounting for prognostic factors. These may
be used to facilitate future trial design and stratification in mUM.
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Introduction
Uveal melanoma is the most common intraocular tumour in
adults and accounts for 3% of all melanomas [1]. Whereas treat-
ment of the primary melanoma is successful in the majority of
cases, metastatic relapse occurs in30% of patients [2–4]. Assays
using a variety of techniques have the ability to analyse the pri-
mary tumour to predict ultimate progression free (PFS)
and overall survival (OS) [5–10]; however to date, there are no
prognostic models in newly diagnosed metastatic disease in
clinical use and reported OS estimates remain in the range of
3–12 months in unselected populations [11].
Further, there is no standard of care treatment in the metastatic
setting where dacarbazine remains a standard control arm in con-
temporary studies despite limited activity [12–14]. Systemic
treatment with a variety of agents has been tested in a multitude
of phase I–II studies examining anti-angiogenics, kinase inhibi-
tors, chemotherapies and immunotherapy [11, 15]. These studies
have been relatively small and, although some have reported
encouraging response rates with heterogeneous survival out-
comes, none have resulted in a successful practice changing phase
III trial. Indeed, it has been challenging to discern the relative sig-
nificance of results from early phase non-randomised trials, due
to lack of standard of care therapies and established benchmarks
for comparison. Understanding prognostic factors and bench-
marks for metastatic uveal melanoma will ultimately facilitate ra-
tional trial design to target appropriate subgroups given the
heterogeneity of disease outcomes. For example, unlike other
cancers, a common therapeutic modality is liver directed therapy
as>80% of patients initially relapse with liver metastases [1, 16];
however data to support improved survival outcomes with this
modality are sparse [11, 15]. Surgical resection may result in
long-term survival outcomes for a few but is not feasible in the
majority due to extent of disease [17]. Given these considerations
[18], we set out to perform a meta-analysis of phase Ib/III trials in
metastatic uveal melanoma using patient level data to address
critical clinical questions.
Methods
Aims of the study
The primary aims were to: (i) To estimate PFS and OS benchmarks to fa-
cilitate planning of future clinical trials, (ii) To identify prognostic
markers which could serve as stratification variables in future trials and
(iii) To explore whether different classes of treatment are associated with
differential outcomes.
Study selection and individual patient level data
Trials were identified from a literature search and reviewed independent-
ly by two investigators (LK, AJ). The literature search was conducted
using PubMed, www.clinicaltrials.gov, the American Society of Clinical
Oncology website (for congress abstracts), Cochrane register of con-
trolled trials and European Society of Medical Oncology meeting
abstracts. Studies were restricted to those published between January
1988 and January 2015 and with a minimum of 10 patients prospectively
enrolled using a therapy for metastatic disease (either systemic or loco-
regional which could be given as any line of treatment). Individual inves-
tigators were then approached by a steering committee (AJ, LK, SS, SP,
RC) to contribute data of all patients treated on protocol. The flow of in-
formation through the phases of the review process (of the literature
search results) according to the PRISMA statement [19] is shown in sup-
plementary Figure S1 (available at Annals of Oncology online).
Individual patient variables at baseline were requested, including age,
sex, Eastern Cooperative Oncology Group (ECOG) performance status,
lactate dehydrogenase (LDH), alkaline phosphatase (ALP), time from
diagnosis of metastatic disease to start of treatment, treatment received,
number of cycles of treatment, line of treatment, number of liver metasta-
ses (10 or<10), percentage involvement of the liver (>50% or50%),
diameter (cm) of the largest liver metastasis, presence of extra-hepatic
liver involvement, the response criteria used in the trial, as well as the best
response achieved and date of best response, date of progression or last
disease evaluation, date of death or last known to be alive. PFS was meas-
ured from the date of first treatment to the date of progression or death
(or censoring). OS was measured from the date of first treatment to death
(or censoring). This meta-analysis was registered in http://www.crd.york.
ac.uk/PROSPERO (registration number CRD42014006965) and
approved by the University Health Network research ethics board (13-
7182-CE).
Statistical analysis
Categorical variables of sex, ECOG status, LDH and ALP [> versus
upper limit of normal (ULN)], and presence or absence of extra-hepat-
ic metastases were summarised with counts and percentages. Continuous
variables such as LDH and ALP were dichotomised and presented as cat-
egorical variables. Variable age was summarised as median with range,
and was categorised (65 versus<65 years). Within the limits of the data
available, the possible prognostic value of all patient characteristics was
assessed, including the year the study was published [analysed as a binary
covariate (2003–2005 versus 2006–2015)].
The following variables were considered in the assessment of prognos-
tic value in univariate and multivariable analysis: ECOG, age (65 versus
<65 years), sex, LDH and ALP level, diameter of the largest liver metasta-
sis (<3 versus 3 cm) and site of metastases (hepatic versus non hepatic
versus both). Binary partitioning techniques were used to obtain the opti-
mum cut-off for the continuous variable of age (65 years). A cut-off for
the diameter of the largest liver metastasis of 3 cm was used, aligned with
the American Joint Committee on cancer substaging of metastatic uveal
melanoma [20] and allowed for appropriate patient numbers in each
group [<3 cm (n¼ 232) versus 3 cm (n¼ 365), n¼ 315 were missing)
for statistical analysis. Other factors relating to liver involvement such as
percentage liver involvement were not included in the model as such vari-
ables were highly correlated with the diameter of the largest liver metasta-
sis. Factors identified as substantial or of interest in univariate analysis
were then assessed in the multivariable setting. In order to account for
missing values in the categorical covariates of interest we included an
additional ‘unknown’ category to prevent loss of power in testing the
remaining non-missing covariates of interest.
Kaplan–Meier product-limit method was used to estimate time-to-
event end point (PFS and OS) distributions, from which, medians and
rates at pre-specified time points (6-month PFS and 1-year OS rates)
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were obtained. Cox proportional hazards model, using sandwich estima-
tor of variance to account for the collinearity of patients within studies,
was used to assess the prognostic importance of different variables (ex-
cept treatment modalities) both at univariate and multivariable level,
based on analyses stratified by treatment modalities. Proportional haz-
ards assumption on each of the prognostic factors was also assessed
graphically by using plots of log of minus log survival probability by log
of time-to-event. Generalised linear mixed models (PROC GLIMMIX
with logit link), that account for the collinearity among patients in the
same study, were used to assess the impact of each of the potential prog-
nostic factors to the binary events (6-month PFS rate and 1-year OS
rate). Exploration of between trial-arm variability in event rates was car-
ried out comparing event rate of each of the treatment arms with the
overall event rate, and whether the trial-arm event rate lies within 95%
confidence interval (CI) of the overall mean based on sample size from
each trial-arm and by examining for outliers.
We carried out sample size calculations for future phase II trials, aim-
ing to improve the 6-month PFS and/or 1-year OS rates observed in our
pooled data [21–26]. Power and sample size were computed using bino-
mial enumeration of all possible outcomes.
All tests were two-tailed, with a probability of<0.05 considered statis-
tically significance. Statistical analyses were carried out using version 9.4
of the SAS System for Windows (SAS Institute, Cary, NC) and the open
source statistical software R version 3.3.1 R Core Team, (R Foundation
for Statistical Computing, Vienna, Austria) (available at http://www.r-
project.org/).
Results
A total of 38 prospective studies were identified and data were
obtained from 29 (76%). Reasons for data not being available
included a lack of investigator response to requests for data and
archived data that were no longer available. Of the 29 studies for
which data were available, 5 involved immunotherapy [27–31], 7
involved a kinase inhibitor (of which 2 were randomised studies
against temozolomide or dacarbazine, respectively) [12, 32–36],
2 used an anti-angiogenic agent [37, 38], 8 involved chemother-
apy (1 of which was a randomised study of intrahepatic versus
intravenous chemotherapy) [39–45] and 7 studies involved intra-
hepatic treatment (chemotherapy or immunotherapy) [46–52]
(supplementary Table S1, available at Annals of Oncology online).
Data were available for a total of 965 patients. Response data
were available for 793 (82%), whilst PFS data were available for
881 (91%) patients, of whom 840 (95%) had progressed or died
and 41 (5%) patients were censored. OS data were available for
912 (95%), of whom 817 (90%) had died and 95 (10%) patients
were alive. There was both PFS and OS data for 873 (90% of
n¼ 965) patients. Therefore, the maximum data available for
analysis were for 912 patients, of which 873 were used for PFS
analysis. Patient characteristics were reflective of contemporary
practice (Table 1). A small number of observations that were cen-
sored before the relevant time point (6 months for PFS and 1 year
for OS) were omitted from analysis of 6-month PFS rate and 1-
year OS rate: 21 (2.4%) and 28 (3%) of patients, respectively.
Determining benchmarks of survival for PFS
and OS
We analysed the complete dataset (n¼ 912 for OS and n¼ 873
for PFS with matching OS data available) to define historical
benchmarks of OS and PFS. The median PFS was
3.3 months (95% CI 2.9–3.6). The 6-month PFS rate was 27%
(95% CI 24 –30); Figure 1A. The median OS was 10.2 months
(95% CI 9.5–11.0). The 1-year OS rate was 43% (95% CI 40–47);
Figure 1B.
Prognostic variables for PFS
Univariate analysis showed that male sex, elevated LDH, elevated
ALP and larger diameter of the largest liver metastasis (3 versus
<3 cm) were associated with shorter PFS (Figure 2A–G).
Multivariable analysis revealed that the same variables except
larger diameter of the largest liver metastasis (3 versus <3 cm)
were associated with shorter PFS. Elevated LDH and elevated
ALP were important factors by multivariable analysis for inferior
6-month PFS rates (Table 2).
Prognostic variables for OS
Prognostic features for shorter OS by both univariate and multi-
variable analysis included higher ECOG (1 versus 0), male sex,
Table 1. Characteristics of patients (data from n5 912)
Characteristic Categories Number (%)
(N5 912)
Sex Male 475 (52)
Female 437 (48)
Age, years (median
61, range 18–90)
<65 550 (60)
65 335 (37)
Missing 27 (3)
ECOG/performance
status
0 475 (52)
1 229 (25)
2–3 21 (2)
Missing 187 (21)
LDH Normal 330 (36)
Elevated (greater than ULN) 386 (42)
Missing 196 (22)
ALP Normal 428 (47)
Elevated (greater than ULN) 162 (18)
Missing 322 (35)
Site of metastases Hepatic alone 473 (52)
Hepatic and extra-hepatic 234 (26)
Extra-hepatic alone 92 (10)
Missing 113 (12)
Diameter of largest
liver metastasis
(cm)
<3 232 (25)
3 365 (40)
Missing 315 (35)
Therapy received Immunotherapy 133 (15)
Anti-angiogenic agents 44 (5)
Kinases 198 (22)
Chemotherapy 306 (34)
Liver directed treatment 231 (25)
Line of therapy (as
defined on indi-
vidual trials)
First line 567 (62)
Second line 126 (14)
Third line or higher 46 (5)
Missing 173 (19)
ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group;
LDH, lactate dehydrogenase; ULN, upper limit of normal.
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elevated LDH, elevated ALP and larger diameter of the largest
liver metastasis (3 versus <3 cm). Higher age (65 versus
<65), male sex, elevated LDH, elevated ALP were significant by
multivariable analysis for 1-year OS (Table 3 and Figure 3A–G).
Of note, the year the study was published was not substantial
for PFS or OS. For all prognostic factors, the proportional haz-
ards assumption appeared not violated (data not shown).
Survival outcomes between treatment groups and
trial-arm variability in 6-month PFS and 1-year OS
Recognising that the time of radiological assessment of disease
varied between studies limiting the accuracy and utility of ana-
lysis, we carried out an exploratory summary of PFS and OS
according to treatment groups. The median PFS for each treat-
ment group was: immunotherapy 2.8 months (95% CI 2.7–3.1),
kinase 2.8 months (95% CI 2.7–3.5), anti-angiogenic 2.8 months
(95% CI 2.6–5.4), chemotherapy 2.6 months (95% CI 2.3–3.0)
and liver directed therapy 5.2 months (95% CI 4.3–5.9), respect-
ively. The median OS for each treatment group was: immuno-
therapy 8.9 months (95% CI 7.0–11.6), kinase 9.1 months (95%
CI 7.0–10.4), anti-angiogenic 11.0 months (95% CI 8.2–15.2),
chemotherapy 9.2 months (95% CI 8.4–10.4) and liver directed
therapy 14.6 months (95% CI 12.6–17.5), respectively,
Figure 4A–B. As an exploratory analysis each treatment group
was analysed individually (supplementary Figure S2A–B, avail-
able at Annals of Oncology online) and the 6-month PFS rates and
the 1-year OS rates for treatment group plotted against group
sample size. This suggested that only the liver directed treatment
arms had a numerically different rate to other treatment modality
arms (77% versus 26% for overall 6-month PFS) and 88% versus
42.5% for overall 1-year OS.
Patient characteristics per treatment group were determined
(supplementary Table S2, available at Annals of Oncology online)
and the difference in prognostic factors explored firstly between
medical treatment modalities and secondly between medical (all
grouped together) and liver directed therapies. ALP and the
diameter of the largest liver metastasis differed between trials
grouped according to medical treatment modality. When
comparing medical to liver directed treatment, gender, age and
diameter of the largest liver lesion differed between these two
groupings (supplementary Table S3, available at Annals of
Oncology online). In order to examine the effect of treatment mo-
dality when controlling for prognostic factors on PFS and OS, we
carried out a multivariable analysis including treatment modality
(liver directed versus medical treatment) which suggested that
liver directed treatment was prognostic for PFS and OS
(supplementary Tables S4 and S5, available at Annals of Oncology
online, respectively).
Determining separate benchmarks of survival for
PFS and OS for medical and liver directed therapy
Given the differences in survival and the prognostic benefit of
liver directed treatment described above we additionally explored
separate benchmarks for medical directed therapy and liver
directed therapy. For medical treatment the median PFS was
2.8 months (95% CI 2.7—2.9), 6-month PFS rate was 21.5%
(95% CI 18.4—24.8), Figure 5A. The median OS was 9.3 months
(95% CI 8.4–10.1). The 1-year OS rate was 38.4% (95% CI 34.7–
42.1), Figure 5B. For liver directed therapy the median PFS was
5.2 months (95% CI 4.3–5.9), the 6-month PFS rate was 43.3%
(95% CI 36.7–49.9); Figure 5C. The median OS was 14.6 months
(95% CI 12.6–17.5). The 1-year OS rate was 57.2% (95% CI 50.5–
63.3); Figure 5D.
Discussion
We aimed to establish benchmarks of survival and prognostic fac-
tors to guide patient care and future trial design. The survival out-
comes we used (6-month PFS and 1-year OS rates) are in line with
a previous analysis of cutaneous melanoma [18], and have added
relevance in the era of immunotherapeutics where traditional
RECIST response rates may imprecisely correlate with OS [53].
Several prognostic factors for overall survival in metastatic
uveal melanoma patients have been proposed from previous
studies [54–56]. Here we sought to validate and build upon these
Figure 1. Kaplan–Meier curves and 95% confidence intervals, for the whole dataset, regarding (A) progression free survival and (B) overall
survival.
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Figure 2. Kaplan–Meier curves for progression free survival from start of treatment according to: (A) Eastern Cooperative Oncology Group
(ECOG), (B) Age, (C) Sex, (D) lactate dehydrogenase (LDH), (E) alkaline phosphatase (ALP), (F) diameter of the largest liver metastasis and (G)
site(s) of metastases.
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in patients participating in clinical trials. Heterogeneity or inter-
actions of factors may imply that many overlap in their prognos-
tic significance and further study will better define the
significance of factors and optimal cut-off values. For example,
the diameter of the largest liver lesion and the percentage liver in-
volvement are both utilised, but both measure tumour bulk.
The difference in outcomes in the different treatment groups is
intriguing. It appears that patients selected for liver directed
Figure 2. Continued.
Table 2. Prognostic factors by univariable and multivariable analysis for progression free survival (PFS)
Variable No. of patients
(n5 873)
PFS distribution 6-month PFS rates
Univariable Multivariable Univariable Multivariable
HR (95% CI) P-value Adjusted
HR (95% CI)
P-value OR (95% CI) P-value Adjusted
OR (95% CI)
P-value
ECOG Performance
0 463 Ref 0.08 Ref 0.13 Ref 0.07 Ref 0.04
1 250 1.15 (0.96–1.38) 1.04 (0.92–1.18) 0.85 (0.58–1.27) 1.07 (0.71–1.62)
Unknown 160 1.32 (0.98–1.79) 1.41 (1.01–1.98) 0.47 (0.25–0.91) 0.42 (0.21–0.84)
Age
< 65 years 540 Ref 0.28 Ref 0.19
> 65 years 333 1.10 (0.93–1.30) 0.80 (0.57–1.11)
Sex
Female 419 Ref <0.001 Ref <0.001 Ref 0.20 Ref 0.10
Male 454 1.22 (1.10–1.35) 1.26 (1.10–1.45) 0.81 (0.59–1.11) 0.76 (0.55–1.06)
LDH
Normal 330 Ref Ref Ref Ref
Elevated > ULN 386 1.66 (1.35–2.04) <0.001 1.53 (1.29–1.82) <0.001 0.33 (0.22–0.49) <0.001 0.37 (0.24–0.56) <0.001
Unknown 157 0.98 (0.73–1.33) 0.97 (0.75–1.26) 0.92 (0.55–1.54) 0.84 (0.47–1.51)
ALP
Normal 428 Ref Ref Ref Ref
Elevated > ULN 162 1.91 (1.49–2.43) <0.001 1.56 (1.25–1.93) <0.001 0.33 (0.19–0.57) <0.001 0.46 (0.26–0.82) 0.03
Unknown 283 1.06 (0.85–1.32) 0.98 (0.79–1.21) 0.82 (0.48–1.38) 0.89 (0.50–1.60)
Diameter of the largest liver metastasis
<3 cm 215 Ref Ref Ref Ref
>3 cm 355 1.37 (1.13–1.66) 0.005 1.20 (1.03–1.39) 0.06 0.66 (0.43–1.01) 0.14 0.93 (0.59–1.46) 0.53
Unknown 303 1.24 (0.90–1.69) 1.10 (0.85–1.44) 0.87 (0.50–1.51) 1.28 (0.72–2.28)
Data were not available for all variables, the maximum number of patients analysed for any variable was 873 for whom both PFS and OS data were
available.
ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; OR, odds ratio; Ref, reference sub-
group; ULN, upper limit of normal.
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treatment have better survival. They may be earlier in the disease
trajectory, but we could not evaluate line of therapy as a factor
due to these data being variably defined in each trial, or their
improved survival may reflect a more indolent disease due to bio-
logical factors or surveillance imaging. Moreover, a recent ana-
lysis suggested that performance status, LDH and diameter of the
largest liver metastasis at baseline may not efficiently predict
prognosis if liver surgery is part of the treatment [56]. Increasing
disease burden in the liver appeared to be associated with
increased disease elsewhere but we were unable to determine
whether the site of first metastases was substantial as previously
reported [57] nor if time from diagnosis of primary tumour or
metastatic disease to start of treatment correlated with increased
disease burden (the data were not obtainable or largely missing in
our dataset).
Importantly, the survival curves that we have generated could
serve to determine whether a new treatment is worthy of further
study and may facilitate the conduction of standard or adaptively
designed trials with appropriately informed benchmarks to lead
to quicker registration of therapeutic agents. Our study emulates
the Korn meta-analysis of phase II trials in cutaneous melanoma
published in 2008 [18]. Benchmarks of PFS and OS were estab-
lished in that study using patient level data from 42 phase II trials
and established criteria to support registrational indications. We
anticipate these data may have similar utility in the future. The
survival curves calculated using our data could be used as the
comparator to new trial data and further study warranted if a spe-
cific significance criterion is met [18]. Alternatively, the observed
PFS or OS rate from our analysis may be used to calculate ad-
equate power and sample size for a prospective trial (supplemen-
tary Tables S6–S8, available at Annals of Oncology online). Using
our data as a whole, 49 patients would be required to test in order
to detect whether a new treatment increases the 6-month PFS
rate by 20% (from the current 27%–47%), at an alpha error of
5% and a power of 80%; if 19 patients have a PFS >6 months
then the new treatment should be investigated further. Similarly
56 patients would be needed to test if the 1-year OS rate is
increased by 20% (from the current 43%–63%) at 90% power; if
Table 3. Prognostic factors by univariable and multivariable analysis for overall survival (OS)
Variable No. of
patients
(n5912)
OS distribution 1 year OS rates
Univariable Multivariable Univariate Multivariable
HR (95% CI) P-value Adjusted
HR (95% CI)
P-value OR (95% CI) P-value Adjusted
OR (95% CI)
P-value
ECOG performance status
0 475 Ref Ref Ref Ref
1 250 1.49 (1.25–1.78) <0.001 1.26 (1.11–1.44) 0.002 0.48 (0.34–0.68) <0.001 0.69 (0.47- 0.16
Unknown 187 1.13 (0.85–1.49) 1.04 (0.86–1.26) 0.76 (0.47–1.23) 0.91 (0.56–1.49)
Age
< 65 years 550 Ref Ref Ref Ref
> 65 years 335 1.21 (1.02–1.43) 0.01 1.12 (0.97–1.31) <0.001 0.66 (0.50–0.89) 0.01 0.68 (0.49–0.93) 0.01
Unknown 27 1.59 (1.16–2.17) 1.76 (1.30–2.38) 0.30 (0.09–1.08) 0.28 (0.09–0.87)
Sex
Female 437 Ref <0.001 Ref <0.001 Ref <0.001 Ref <0.001
Male 475 1.38 (1.18–1.60) 1.41 (1.16–1.72) 0.60 (0.45–0.79) 0.56 (0.41–0.75)
LDH
Normal 330 Ref Ref Ref Ref
Elevated > ULN 386 2.64 (2.11–3.30) <0.001 2.31 (1.87–2.87) <0.001 0.16 (0.11–0.22) <0.001 0.19 (0.13–0.28) <0.001
Unknown 196 1.89 (1.38–2.59) 1.64 (1.13–2.36) 0.34 (0.22–0.52) 0.41 (0.27–0.64)
ALP
Normal 428 Ref Ref Ref Ref
Elevated > ULN 162 2.76 (2.27–3.36) <0.001 1.98 (1.61–2.42) <0.001 0.20 (0.12–0.32) <0.001 0.36 (0.22–0.59) <0.001
Unknown 322 1.37 (1.13–1.67) 1.12 (0.90–1.38) 0.68 (0.44–1.04) 0.92 (0.62–1.37)
Diameter of the largest liver metastasis
<3 cm 232 Ref Ref Ref Ref
>3 cm 365 1.65 (1.41–1.93) <0.001 1.26 (1.10–1.45) 0.002 0.42 (0.29–0.60) <0.001 0.69 (0.46–1.03) 0.17
Unknown 315 1.34 (1.01–1.78) 1.25 (0.97–1.63) 0.70 (0.44–1.10) 0.91 (0.56–1.46)
Data were not available for all variables, the maximum number of patients analysed for any variable was 912.
ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; OR, odds ratio; Ref, reference sub-
group; ULN, upper limit of normal.
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Figure 3. Kaplan–Meier curves for overall survival according to: (A) Eastern Cooperative Oncology Group (ECOG), (B) Age, (C) Sex, (D) lactate
dehydrogenase (LDH), (E) alkaline phosphatase (ALP), (F) diameter of the largest liver metastasis, (G) site(s) of metastases.
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31 patients have an OS> 1 year then further trial of this treatment
is warranted. The benchmarks for systemic therapy or liver
directed therapy could be similarly utilised (supplementary
Tables S7 and S8, available at Annals of Oncology online).
Whilst informative, our study has limitations: (i) patients
included in this analysis were fit for clinical trials, generally
ECOG 0–1 with preserved organ function (ii) whilst all trials
were carried out prospectively the data used in our analysis was
obtained from prospectively collected records or collected retro-
spectively and in some cases the completeness of the data (not all
data fields were collected by all investigators) limited the analysis
and (iii) we produced population wide benchmarks and sub-
groups benchmarks according to therapy. The inclusion of liver
directed therapies in an overall benchmark analysis could in-
crease heterogeneity of the study population given that these
treatments are given in cases of isolated liver disease and are not
consistent with the systemic nature of the other treatments;
however, many patients with liver only disease still receive sys-
temic therapies.
Our analysis needs refinement, as our datasets enlarge, to sim-
plify and improve the accuracy and utility of the prognostic fac-
tors. We were limited in our ability to explore the effect of liver
tumour bulk on prognosis and the effect of subsequent
treatments after trial participation on survival was also unknown
as we did not have access to this data. Lastly the ability to define a
population suitable for liver only directed treatment will lead to
distinct treatment paradigms and require different survival
benchmarks for trial design, a possibility we explore here but one
that requires further work.
In conclusion, our meta-analysis indicates that PFS and OS
from metastatic uveal melanoma remain poor in clinical trials
published over the last 13 years. The benchmarks and analyses
provided here may guide future trial design in metastatic uveal
melanoma patients where a standard of care is yet to be defined.
In light of our analysis, we encourage investigators globally to
continue to collaborate to improve the staging, prognostication
and care of patients with metastatic uveal melanoma.
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Figure 3. Continued.
Figure 4. Kaplan–Meier curves according to treatment modality received, regarding (A) progression free survival and (B) overall survival.
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